Purple Biotech Ltd. — 2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; separate Q4 results are not provided in the supplied filing text. Financial statements are prepared under IFRS as issued by the IASB and reported in U.S. dollars.
Business context
Purple Biotech is a clinical-stage oncology company with no marketed oncology products and no material recurring product revenue. Its pipeline comprises CM24, an anti-CEACAM1 antibody; NT219, a small molecule targeting IRS1/2 and STAT3; and IM1240, the lead candidate in its preclinical tri-specific antibody platform. The company discontinued Consensi activities in 2021 and reports oncology as its operating focus.
Key financial metrics
| Metric (US$ millions, except per-ADS data) | 2023 | 2022 |
|---|---|---|
| Revenue | No revenue from oncology candidates; the filing reports no clear FY2023 revenue value | No revenue from oncology candidates |
| Research and development expense | 17.0 | 16.3 |
| General and administrative expense | 5.2 | 6.3 |
| Operating loss | 22.3 | 22.6 |
| Net loss | 20.0 | 21.8 |
| Net loss per ADS | $0.90 | $1.20 |
| Net cash used in operating activities | 19.9 | 16.7 |
| Cash and cash equivalents | 14.5 | 15.0 |
| Short-term deposits | 0.9 | 16.7 |
| Total current assets | 15.8 | 33.3 |
| Total current liabilities | 7.2 | 7.1 |
Cash, cash equivalents and short-term deposits totaled $15.3 million at year-end, down from $31.7 million. Management said available resources were sufficient for at least the next 12 months, while also stating that additional financing or spending reductions may be needed thereafter. The company had no borrowings; liabilities included lease obligations and a $2.5 million warrant liability. The current ratio was approximately 2.2x. Gross margin is not meaningful for this development-stage business.
Material changes versus prior year
- R&D expense rose 4%, primarily from ongoing NT219 and CM24 trials, partly offset by lower CMC activity. G&A expense fell by about $1.0 million, mainly due to lower compensation-related and insurance costs.
- Operating loss narrowed slightly, while net loss declined by $1.8 million, mainly reflecting higher net finance income and lower G&A expense. Net finance income included a material non-cash warrant fair-value gain; the filing reports a $3.5 million gain on warrant remeasurement.
- Operating cash use increased by $3.2 million. The reduction in short-term deposits and acquisition spending contributed to the year-end liquidity decline.
- In February 2023, Purple acquired Immunorizon for $3.5 million in cash and $3.5 million in ADSs, with up to $94 million in long-term milestones plus royalties. The acquisition added the preclinical tribody platform and IM1240.
Outlook, management commentary and key risks
- Pipeline milestones: CM24 Phase 2 enrollment in metastatic pancreatic cancer was completed in December 2023. Management expected interim results in the first half of 2024 and topline results by year-end 2024. In February 2024, the company set NT219’s recommended Phase 2 dose with cetuximab at 100 mg/kg and planned a Phase 2 head-and-neck cancer study in the first half of 2024. The company expected to submit an IND for IM1240 in approximately two years.
- Clinical evidence remains preliminary: The filing describes early NT219 combination-arm responses and CM24 early-stage findings, but neither candidate is approved. Clinical efficacy, safety, trial completion, regulatory approval, manufacturing scale-up, reimbursement and commercial viability remain uncertain.
- Funding and dilution: Purple expects continued losses and substantial R&D spending and may need further capital. The October 2023 financing raised $5 million gross and included immediately exercisable warrants; the company also has a shelf registration and an ATM facility. Future equity issuance or warrant exercises could dilute shareholders. As of March 5, 2024, the company reported 265.6 million ordinary shares outstanding.
- NASDAQ listing: On January 25, 2024, Purple received notice that its ADS bid price had been below $1.00 for 30 consecutive business days. The initial compliance period ran through July 23, 2024; delisting could reduce liquidity and impair access to capital.
- Israel-related exposure: The company reported no material trial interruptions to date, but five of 27 CM24 and NT219 study sites were in Israel. Ongoing conflict, employee reserve duty, travel or supply disruptions and difficulty raising capital could affect operations. Commercial insurance does not cover losses associated with the regional security situation.
- Contingencies: A surviving Israeli class-action motion alleges damages of approximately NIS 29 million (about $8.2 million); management rejects the claims and says it cannot reliably assess probability or exposure. The Atzmon claim seeks approximately NIS 9 million (about $2.5 million); mediation was expected in March 2024. No provision was recorded for these matters. The 2015 class-action motion and a related separate lawsuit were dismissed in 2023.
- Other exposures: IIA-funded technology carries royalty obligations and restrictions on manufacturing and transferring know-how outside Israel; the disclosed contingent IIA obligation, including interest, was $2.3 million. The company also depends heavily on third-party manufacturers, CROs and collaborators, and faces patent, cybersecurity, foreign-exchange and healthcare-pricing risks.
- Audit and controls: The auditor issued an unqualified IFRS opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not express an opinion on internal-control effectiveness. Fair value of intangible assets was identified as a critical audit matter, involving subjective assumptions about development costs, success rates, future revenues and discount rates.
Important facts for investors to verify
- Obtain subsequent filings for CM24 interim and topline results, NT219 Phase 2 initiation and any updated clinical safety or efficacy data.
- Confirm actual cash runway, quarterly cash burn, financing plans and any post-year-end capital raises or material changes to liquidity.
- Review the warrant terms, potential share issuance and dilution, and the status of the NASDAQ minimum-bid-price compliance process.
- Track the status and accounting treatment of the Surviving Motion and Atzmon claim, including any settlement, provision or change in estimated exposure.
- Assess the assumptions supporting the $28.0 million carrying value of intangible assets and monitor for impairment indicators.